Trading Report: Today: Prudential Financial Inc. reduces its investment in Hologic Inc. (HOLX)

Today: Prudential Financial Inc. reduces its investment in Hologic Inc. (HOLX)

Prudential Financial Inc. reduced its stake in Hologic Inc. (NASDAQ:HOLX) by 8.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,290,490 shares of the company’s stock after selling 323,291 shares during the period. Prudential Financial Inc. owned approximately 1.19% of Hologic worth $127,770,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC increased its position in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares in the last quarter. Norinchukin Bank The increased its position in shares of Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares in the last quarter. US Bancorp DE increased its position in shares of Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares in the last quarter. Calvert Investment Management Inc. increased its position in shares of Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares in the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in shares of Hologic by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 10,559 shares of the company’s stock worth $410,000 after buying an additional 144 shares in the last quarter. 92.95% of the stock is owned by institutional investors and hedge funds.

Hologic Inc. (NASDAQ:HOLX) opened at 38.66 on Monday. The firm has a 50-day moving average price of $37.88 and a 200 day moving average price of $36.82. Hologic Inc. has a 12 month low of $31.84 and a 12 month high of $41.66. The stock has a market capitalization of $10.76 billion, a PE ratio of 33.33 and a beta of 1.13.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 2nd. The company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.02. The business earned $726.80 million during the quarter, compared to analyst estimates of $721.52 million. Hologic had a return on equity of 26.76% and a net margin of 11.68%. Hologic’s revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 EPS. Equities analysts anticipate that Hologic Inc. will post $2.15 earnings per share for the current year.

A number of brokerages recently commented on HOLX. Leerink Swann restated an “outperform” rating and set a $46.00 target price on shares of Hologic in a report on Monday, October 3rd. Barclays PLC restated a “buy” rating and set a $45.00 target price on shares of Hologic in a report on Thursday, November 3rd. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Thursday, November 3rd. Finally, Royal Bank Of Canada increased their price objective on Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a report on Monday, August 1st. Six research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $43.20.

In other Hologic news, VP Karleen Marie Oberton sold 31,470 shares of Hologic stock in a transaction on Monday, October 10th. The stock was sold at an average price of $40.00, for a total transaction of $1,258,800.00. Following the completion of the sale, the vice president now directly owns 17,005 shares of the company’s stock, valued at approximately $680,200. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elaine Ullian sold 18,236 shares of Hologic stock in a transaction on Monday, October 10th. The shares were sold at an average price of $39.88, for a total value of $727,251.68. Following the sale, the director now directly owns 42,898 shares of the company’s stock, valued at $1,710,772.24. The disclosure for this sale can be found here. Company insiders own 0.84% of the company’s stock.

Hologic Company Profile

Related posts

Leave a Comment